Dr. Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The work he and his team have performed has been instrumental in pushing forward current lung cancer treatments.

Following a PhD in molecular biology at the Medical Research Council’s Laboratory of Molecular Biology at the University of Cambridge, UK, Dr. Camidge completed his medical training at the University of Oxford, UK. He then became the first person to train in both medical oncology and clinical pharmacology in the UK, before joining the University of Colorado, USA, in 2005. Expertscape ranked him as one of the top 10 US physicians who specialize in lung cancer in 2020 and as a ‘World Expert’ (one of the top scholars writing about lung neoplasms over the past decade) in 2019. He has authored over 300 academic publications, including in the Journal of Thoracic Oncology, The Lancet Oncology, and The New England Journal of Medicine. He has received numerous awards, such as the ‘A Breath Away From The Cure’ Award from the Lung Cancer Foundation and the international Bonnie J. Addario Lectureship Award.

Dr. Camidge is the national medical director of the Academic Thoracic Oncology Medical Investigators Consortium (a collaborative network of 15 US and Canadian sites conducting trials in thoracic oncology), co-chair of the Elsevier ClinicalPath (formerly Via Oncology) Lung Cancer Pathways Committee, and a past member of the Non–Small Cell Lung Cancer, Mesothelioma, and Thymic Cancer committees of the National Comprehensive Cancer Network.